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Research Article
Drug-induced chromatin accessibility changes associate
with sensitivity to liver tumor promotion
Antonio Vitobello1,3,* , Juliane Perner1,*, Johanna Beil1, Jiang Zhu2, Alberto Del Rı´o-Espı´nola1, Laurent Morawiec1,
Magdalena Westphal1, Vale´rie Dubost1, Marc Altorfer1, Ulrike Naumann1, Arne Mueller1, Karen Kapur1, Mark Borowsky2,
Colin Henderson4,6 , C Roland Wolf4,6, Michael Schwarz5,6, Jonathan Moggs1,6, Re´mi Terranova1
Liver cancer susceptibility varies amongst humans and between
experimental animal models because of multiple genetic and
epigenetic factors. The molecular characterization of such sus-
ceptibilities has the potential to enhance cancer risk assessment of
xenobiotic exposures and disease prevention strategies. Here,
using DNase I hypersensitivity mapping coupled with transcriptomic
proﬁling, we investigate perturbations in cis-acting gene regulatory
elements associated with the early stages of phenobarbital (PB)-
mediated liver tumor promotion in susceptible versus resistant
mouse strains (B6C3F1 versus C57BL/6J). Integrated computational
analyses of strain-selective changes in liver chromatin accessibility
underlying PB response reveal differential epigenetic regulation of
molecular pathways associated with PB-mediated tumor promotion,
including Wnt/β-catenin signaling. Complementary transcription
factor motif analyses reveal mouse strain–selective gene regulatory
networks and a novel role for Stat, Smad, and Fox transcription
factors in the early stages of PB-mediated tumor promotion.
Mapping perturbations in cis-acting gene regulatory elements
provides novel insights into the molecular basis for susceptibility
to xenobiotic-induced rodent liver tumor promotion and has the
potential to enhance mechanism-based cancer risk assessments
of xenobiotic exposures.
DOI 10.26508/lsa.201900461 | Received 20 June 2019 | Revised 26 September
2019 | Accepted 26 September 2019 | Published online 15 October 2019
Introduction
Hepatocellular carcinoma (HCC) is the most common primary
malignancy of the liver. Chronic liver disease due to hepatitis B virus
or hepatitis C virus and alcohol accounts for the most HCC cases,
but HCC has a multitude of etiological risk factors, including the
baseline genetic and epigenetic makeup and multiple environ-
mental cues such as aﬂatoxin and exposure to chemicals and
pharmaceuticals (Gariboldi et al, 1993; Dragani, 2010; Ghouri et al,
2017). Hepatocarcinogenesis is an extremely complex, multistep
process involving prominent environment-induced genetic and
epigenetic alterations ultimately leading to malignant trans-
formation of the hepatocytes (Farber, 1984; Pogribny & Rusyn, 2014).
Although key pathways associated with HCC initiation are emerging,
the molecular basis for strain-, gender- or species susceptibilities
to HCC is still poorly understood. The identiﬁcation of the underlying
mechanism-based molecular alterations that drive hepatocyte trans-
formation and promote development and progression of HCC is critical
for its detection, therapeutic intervention, prevention, and for cancer
risk assessment of chemical and pharmaceutical products.
Epigenetic variation, together with genetic variation and meta-
genomic variation, represent key drivers of phenotypic variation in
health and disease. Notably, epigenetic signatures are strongly
inﬂuenced by the environment and determine phenotypic re-
sponses in health and disease (Jirtle & Skinner, 2007; Feil & Fraga,
2012). Epigenetic alterations can occur during the early stages of
malignancy, plausibly remaining latent until further stimulation by
endogenous or environmental factors (Feinberg et al, 2016;
Vicente-Duenaset al, 2018). Multiple layers of epigenetic marks
and mechanisms control genome function (Allis & Jenuwein, 2016).
Methods for proﬁling chromatin accessibility, including DNase I
hypersensitivity mapping, enable the identiﬁcation of cis-acting
gene regulatory elements (or cistrome) that are important for
determining cell type identity and functions. The cistrome includes
well-characterized DNA sequence elements such as enhancers and
promoters and is strongly enriched for transcription factor (TF)-
binding sites, providing critical genome regulatory information, but
not limited to gene expression regulation (Consortium, 2012; Shen
et al, 2012; Thurman et al, 2012; Johanson et al, 2018). Notably, recent
integration of regulatory DNA and disease- and trait-associated
genetic variant catalogs have demonstrated a disproportionate (>80%)
enrichment of disease-associated genetic variants in noncoding
enhancer regions. The genetic variants were reported to disrupt
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important cell type–speciﬁc TF regulatory interactions (Maurano
et al, 2012; Hnisz et al, 2013; Pennacchio et al, 2013; Mifsud et al, 2015)
and were associated with a broad range of phenotypic effects,
sometimes driven by subtle effects on target gene expression
(Corradin et al, 2014; Soldner et al, 2016). The perturbation of
regulatory regions, including enhancers, plays an important role
during the tumorigenic process (Davie et al, 2015; Sur & Taipale,
2016). Thus, mapping such perturbations during spontaneously
occurring or environmentally driven carcinogenesis has high po-
tential for identifying early mechanism-based biomarkers of car-
cinogenesis (Thomson et al, 2014; Luisier et al, 2014b).
Several rodent models have been used in deﬁning the patho-
genesis of HCC and have contributed to the current knowledge of
HCC (Heindryckx et al, 2009; Santos et al, 2017). Treatment of mice
with phenobarbital (PB) represents one of the best characterized
models of xenobiotic-induced liver tumor promotion and has been
extensively evaluated to investigate the kinetics and molecular
drivers associated with drug-induced rodent non-genotoxic hep-
atocarcinogenesis. We previously reported that PB-mediated liver
tumor promotion is accompanied by signiﬁcant progressive tran-
scriptional, epigenetic (DNA methylome and hydroxymethylome),
and TF regulatory changes preceding liver-speciﬁc tumorigenic
events, some of the changes plausibly reﬂecting dedifferentiation/
reprogramming of hepatocytes towards a stem cell–like state (Bachman
et al, 2006; Phillips et al, 2009a; Lempiainen et al, 2011, 2013; Thomson et al,
2012, 2016; Luisier et al, 2014b).
Although commonly considered a “rodent” non-genotoxic liver
carcinogen, signiﬁcant species and strain differences (qualitative
and quantitative) have been observed for PB-mediated liver tumor
promotion, highlighting preexisting differences in baseline tumor
susceptibilities (Table S1) (Peraino et al, 1973; Becker, 1982; Diwan
et al, 1986; Goldsworthy & Fransson-Steen, 2002). PBpositively selects
for β-catenin (Ctnnb1)-mutated liver tumors in themouse, although
inhibiting the outgrowth of mouse liver tumors that harbor an
activated MAPK-pathway (i.e., Ha-ras or B-raf–mutated) (Aydinlik
et al, 2001; Calvisi et al, 2004). Sensitive mouse strains (e.g., C3H or
the hybrid strain B6C3F1) develop Ctnnb1-mutated neoplasms within
12 mo of PB exposure with high incidence, whereas tumor-resistant
strains (e.g., C57BL/6) only develop liver tumors after an initiating
mutagenic event and long-term PB exposure (Table S1 and refer-
ences within).
At the molecular level, divergent transcriptional signatures have
been identiﬁed inmouse strains exhibiting differential sensitivity to
PB-driven tumor promotion effects (Phillips et al, 2009b), further
supporting the impact of genetic and epigenetic variation on TFs
and gene regulatory networks responsible for differential tran-
scriptional readouts in response to PB.
Here, we have exploited established mouse strain–speciﬁc dif-
ferences in sensitivity to PB-mediated tumor promotion to explore
drug-induced chromatin regulatory and transcriptional variations
underlying phenotypic responses at early stages of liver tumor
promotion. We used genome-wide DNase I hypersensitivity proﬁling
(DNase-seq) of liver tissue after treatment of mice with tumor-
promoting doses of PB in both tumor-resistant C57BL/6J and
tumor-prone hybrid B6C3F1 (C57BL/6 female × C3H/He male) strains.
Our analysis reveals quantitative strain differences in hepatic
molecular responses to PB at both transcriptional and chromatin
accessibility levels, including genes that regulate Wnt/β-catenin
signaling. Most PB-mediated chromatin accessibility changes
occurred at distal intergenic (IG) regions that were on average
~45 kb away from the nearest gene transcriptional start site (TSS),
plausibly mapping to the location of cis-acting gene regulatory
elements. The analysis of TF motifs underlying these pre-
dominantly strain-selective changes in chromatin accessibility
highlights several novel candidate transcriptional co-regulators
that may underlie the sensitivity of B6C3F1 mice to PB-mediated
liver tumor promotion. These data also highlight the signiﬁcant
potential of mapping tissue-speciﬁc changes in cis-acting gene
regulatory elements for providing novel insights into the mo-
lecular basis of xenobiotic-induced phenotypes, including the
potential to enhance mechanism-based cancer risk assessments
of xenobiotic exposures.
Results
Experimental model for comparing mouse strain sensitivity to
PB-mediated tumor promotion
Molecular proﬁling of well-characterized mouse strains that exhibit
differences in sensitivity to PB-mediated liver tumor promotion
represents an ideal model system for identifying early mechanism-
based markers of drug-induced liver tumorigenesis. We previously
reported kinetic investigations of early hepatic pathological and
transcriptional effects associated with PB treatment (ad libitum
access to 0.05% [wt/vol] in drinking water for up to 91 d of treat-
ment) in B6C3F1 (Lempiainen et al, 2013) and C57BL/6J (Luisier et al,
2014a) mouse strains. In these studies, PB concentrations in plasma
and liver were determined by liquid chromatography–mass spec-
trometry and showed comparable and stable plasma levels of PB
over time (Fig S1). This treatment regimen reportedly promotes high
incidence of tumor formation exclusively in the B6C3F1 mouse
strain in absence of mutagenic priming events (Table S1). Despite
such differences in tumor promotion effects after long-term (≥1 yr)
treatment, the liver histopathology phenotype induced by treat-
ment at earlier time points was essentially identical in both strains
and limited to hepatocellular hypertrophy (primarily of perivenous
hepatocytes in the central zone of the lobule), starting from 8 d of
PB treatment and increasing in severity at later time points
(Lempiainen et al, 2013; Luisier et al, 2014a). Thus, this experimental
setup enables the investigation of chromatin and transcriptional
effects underlying early events of liver tumor promotion sensitivity.
Differential chromatin accessibility maps of PB-treated mouse
livers
We hypothesized that the mapping of PB treatment-mediated
hepatic transcriptional and epigenetic effects (δ = PB response),
and their comparison across mouse strains (Δ = strain-selective PB
effects) may enable the characterization of key gene regulatory
elements and associated TFs underlying differential tumorigenicity
outcomes after chronic PB exposure (Fig 1A).
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Figure 1. DNase hypersensitivity mapping of PB-treated mouse (B6C3F1 and C57BL/6J) livers.
(A) Overview of experimental design and analysis plans. Mouse strains of differential tumor promotion sensitivity were PB-treated for 91 d in comparable conditions
and with comparable histopathological outcomes. Their livers were processed to proﬁle transcriptome (RNA-seq) and open chromatin landscape (DNase-seq). PB
response effects (δ) are compared across strains (Δ) using different computational approaches. (B) Proﬁles of PB-mediated open chromatin changes
(|log2 FC| ≥ 0.58, FDR < 0.01) in livers of B6C3F1 and C57BL/6J. Windows of 5 kb (−2.5 to +2.5 kb) centered around each identiﬁed δ-DHS are illustrated.
Log2-transformed DHS fragment counts in consecutive 50-bp bins within the 5-kb window scaled to average library size are shown. Color intensity from low to high
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Mapping chromatin accessibility landscapes can help elucidate
key genome regulatory regions (e.g., gene promoters and en-
hancers) and associated epigenetic mechanisms of gene regulation
(Consortium, 2012; Thurman et al, 2012). We, thus, proﬁled gene
expression and chromatin accessibility landscapes in tumor-
resistant C57BL/6J and hybrid tumor-prone B6C3F1 male mice af-
ter 91 d of PB treatment using archived tissues from our previously
reported kinetic studies (Lempiainen et al, 2013; Luisier et al, 2014a).
To gain insight into the gene regulatory landscape accounting for
PB-mediated responses, we performed DNase I digestion combined
with high-throughput sequencing (DNase-seq) on individual liver
samples isolated from control and treatment groups (n = 4–5) of
C57BL/6J and B6C3F1 mice. A consensus set of 98,170 DNase I hy-
persensitive sites (DHSs) was identiﬁed that show signiﬁcant DHS
signal in at least three samples. The obtained DNase-seq proﬁles are
overall comparable with 8-wk-old mouse liver DNase-seq publicly
available from ENCODE (Pearson’s correlation coefﬁcients 0.86–0.91;
Fig S2A). DHS signals from individual samples show high degree of
reproducibility across samples (Pearson’s correlation coefﬁcients
0.55–0.98). The unsupervised clustering and Principal Component
Analysis (PCA) based on the top 5,000 most variable DHSs (Fig S3A
and B) show that strain background (PC1) is the strongest source of
variation among samples, whereas the treatment effects is less
strong but consistent (PC3). Overall, this indicates that DNase-seq is a
robust method to detect strain- and PB-mediated variations in ac-
cessible chromatin regions genome wide.
Using library size–adjusted read counts at each DHS as direct
quantitative readout of chromatin accessibility, we performed
differential DHS analysis between vehicle- and PB-treated sample
groups (δ-DHS). Using |log2 Fold Change (FC)| ≥ 0.58 and False
Discovery Rate (FDR) ≤ 0.01 as cutoffs, we found a comparable
number of PB-mediated differentially accessible δ-DHSs in B6C3F1
(n = 864) and C57BL/6J (n = 811) and comparable direction of
increased/reduced chromatin accessibility effects across strains
(Fig 1B and Table S2). Interestingly, we identiﬁed δ-DHSs at both
promoter and upstream regulatory regions of well-characterized
transcriptionally induced PB-responsive and constitutive andros-
tane receptor (CAR)–regulated target genes, such as Cyp2b10 and
Cyp2c55 (Honkakoski & Negishi, 1997; Konno et al, 2010; Lempiainen
et al, 2011) (Fig 1D and E).
To investigate which fraction of the functional genome was most
affected by treatment-related changes, we ﬁrst mapped the δ-DHSs
to annotated promoters, intragenic and intergenic regions. We
found overall enrichment of the δ-DHSs in intergenic regions and
under-representation at promoter regions (here deﬁned as the
1,000-bp region upstream of the Transcriptional Start Site (TSS) (Fig
1C), indicating that chromatin accessibility changed mostly at
intergenic regulatory elements. Next, we investigated the activity
status of the δ-DHSs at baseline using the histone modiﬁcation
proﬁles (H3K4me3, H3K4me1, H3K27ac, and H3K9ac) from the 8-wk-
old mouse liver in ENCODE, which showed chromatin accessibility
proﬁles consistent with our data. The integration of these four histone
modiﬁcation readouts to theopenDHS landscapeenables a functional
partitioning of the genomic landscape (including constitutively opened
promoter regions and tissue-speciﬁc active, poised, or silent enhancer
regions) (Ram et al, 2011; Shlyueva et al, 2014). Aligning the histone
modiﬁcation proﬁles to the consensus set of DHSs, thus, revealed
expected functional clustering of promoters (cluster I), active (cluster
II), poised (cluster III), and inactive enhancers (cluster IV) (Fig S2B). This
analysis revealed that the PB-mediated changes in open chromatin
landscape in both strains were strongly enriched in cluster IV, whereas
depleted at active chromatin clusters I and II (Fig S2C). We, however,
noted that functionally active enhancer regions (cluster II) tended to
show stronger enrichment for B6C3F1 over C57BL/6J, suggestive of a
strain-speciﬁc effect in PB-mediated δ-DHS distribution.
Overall, our DNase-seq data robustly identiﬁes a landscape of PB
treatment–related regulatory chromatin changes. In both mouse
strains, most δ-DHSs indicate increased chromatin accessibility
and are enriched in intergenic regions, plausibly representing
poised or inactive enhancer regions in the mouse liver.
Quantitative strain differences in PB-mediated liver chromatin
accessibility changes
To evaluate the consistency of global chromatin accessibility effects
in both strains, we projected the δ-DHSs (from Fig 1B) over the
consensus DHS landscape in both strains (Fig 2A). We found that a
subset of δ-DHSs is common to both strains (n = 319). These “shared”
effects tend to occur in regions of strongest DHS log2 FC (Fig 2B) and
are most consistent across replicates (Fig 2C). A comparable number
of δ-DHSs only reached the cutoffs in one of the strains, with 545 and
492 δ-DHSs selectively enriched in B6C3F1 and C57BL/6J, respectively
(Fig 2A). Direct visual comparison of the DHS landscapes (Fig 2C)
points to coherent trends of the selectively enriched chromatin
accessibility changes in both strains. Still, the differential analysis
highlights differences of the effects inmagnitude and/or consistency
across replicates (only reaching the statistical thresholds in one of
the strains). Taken together, the observed δ-DHSs are consistent with
discrete cell-autonomous differences in molecular regulation and/
or changes in small subsets of liver cells, rather than large changes in
tissue composition or lineage identity after PB treatment.
Many coding genes are well annotated with their biological
functions. Noncoding regions, however, typically lack such anno-
tation. We next associated each Δ-DHS to the nearest TSS (Fig 2D),
which is on average 45 kb away and can be located over 1,000 kb
away (Fig 2E). Notably, whereas the shared DHSs follow the same
bimodal (TSS and distal) distribution as the whole-genome DHS
landscape, the strain-selective Δ-DHS landscape tends to distribute
away from TSS, possibly accounting for distal enhancer-based
changes (Fig 2E). This DHS–TSS proximity calling enabled us to
build gene lists for each shared or strain-selective DHS group
among which several well-known gene targets of PB signaling were
identiﬁed (Table S2).
represents signals within the range (1.5, 7). Individual samples are separated by grey lines. (C) Relative genomic distribution of δ-DHS with respect to UCSC genome
annotation. (D, E) Genome browser tracks show δ-DHS effects at the promoter and proximal regulatory regions of two PB-responsive genes Cyp2b10
and Cyp2c55.
Chromatin and gene regulatory effects in liver tumorigenesis Vitobello et al. https://doi.org/10.26508/lsa.201900461 vol 2 | no 5 | e201900461 4 of 18
Figure 2. Quantitative strain-selective chromatin accessibility effects (Δ-DHS) upon PB treatment in mice.
(A) Volcano plot showing the log2 FC and P-values of all genes (light grey) from the differential tests using the C57BL/6J samples (ﬁrst row) or the B6C3F1 samples
(second row). The 319 common (red), 545 B6C3F1-enriched (orange) and 492 C57BL/6J-enriched (purple) differentially expressed genes are highlighted. Dashed lines
indicate selected statistical cutoffs (|log2 FC| = 0.58 and P-value corresponding to FDR = 0.01). (B) Linear correlation of Log2 FC PB treatment DHS effects across strains. Only
Δ-DHS effects supported by either strain are shown and used to ﬁt the linear regression line indicated by the dashed line. (C)Head-to-head comparison of PB-mediated
δ-DHS effects, highlighting shared (n = 319, red box) and unique strain effects (n = 545 for B6C3F1, orange box and n = 492 for C57BL/6J, purple box). Δ-DHS effects were
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Acknowledging the limitations of DHS–TSS proximity calling and
the risk that a fraction of gene hits may not be biologically relevant,
we further analyzed the gene hits to identify common underlying
biological functions within each shared or strain-selective gene
group. We performed network enrichment analysis using the Search
Tool for the Retrieval of Interacting Genes/Proteins (STRING data-
base) (Jensen et al, 2009) to identify enrichment in protein–protein
interaction partners. Consistent with the well-characterized PB-
mediated hepatic xenobiotic response, STRING-db sub-networks
enriched in shared DHS–TSS highlighted phase I metabolism
genes (e.g., Cyp2b10, Cyp2c55, etc.) as well as signal transduction
genes (e.g., Stat3, Pten, etc.) (Fig 2A and Table S3). Themost connected
genes in the STRING-db sub-networks enriched in B6C3F1 Δ-DHS–
associated genes pointed out important regulatory factors, including
Klf4, a key regulator of stem cell pluripotency (Takahashi et al, 2007;
McConnell & Yang, 2010), Wnt/β-catenin signaling genes such as
Wnt16 and Tcf7l2 (alias Tcf4) (network 4), and Src (network 6), which
was previously reported to contribute PB-mediated mode-of-action,
including through β-catenin signaling regulation (Groll et al, 2016).
The C57BL/6J Δ-DHS group showed unique Ctnna1 (network 14)
enrichment and other effects related to metabolism, cell cycle, and
differentiation (Fig 2A and Table S3).
We previously reported CAR and Wnt/β-catenin signaling–
dependent transcriptional effects at the pluripotency-associated
Dlk1-Dio3 imprinted gene cluster noncoding RNAs in the liver of
mice treated with tumor-promoting doses of PB (Lempiainen et al,
2013; Pouche et al, 2017). Importantly we identify a minimal, but sig-
niﬁcant B6C3F1-speciﬁc increase in chromatin accessibility within the
Dlk1-Dio3 cluster upstream of the Meg3 locus and at close proximity
(within 500 bp) to the reported imprinting control region (Nowak et al,
2011), consistently we also measured enhanced Meg3 transcriptional
up-regulation in B6C3F1 liver material (Table S2 and Fig S4).
Strain-selective PB-mediated liver transcriptional changes
To enable further functionalization of the DHS open regulatory
landscape effects, we ran genome-wide RNA sequencing from
matching liver samples. The RNA sequencing data were strongly
clustered per strain and treatment effects, and PCA analyses of the
top 1,000 most variable genes also show that strain background
(PC1) and PB response (PC2) together account for most of the
variation in the data (Fig S3C and D). Using cutoffs of log2 FC ≥ 0.58
and FDR < 0.01, we identiﬁed 127 differentially expressed genes in
C57BL/6J and 269 in B6C3F1 samples (Table S4). Akin to the DHS
landscape, we ﬁnd predominant transcriptional perturbrations in a
strain-selective manner. 102 genes are commonly regulated and
tend to affect genes associated with the strongest transcriptional
expression changes, whereas 167 and 25 genes are selectively
modulated in B6C3F1 and C57BL/6J, respectively (Fig 3A and B). The
effects are qualitatively consistent across strain and replicates (Fig
3C), thus again highlighting that strain differences pertain to
quantitative effects in these total liver analyses.
Gene ontology (GO) term over-representation analyses showed
enrichment for genes relevant to xenobiotic response in both
strains (data not shown), whereas STRING-db protein–protein in-
teraction enrichment analyses highlighted biologically signiﬁcant
B6C3F1-speciﬁc Δ-RNA changes. For example, of genes relevant to
PB-mediated regulation of Wnt/β-catenin signaling (Cdh1 or Src in
networks 4 and 2) and other genes involved in important signaling
functions in the liver such as Tgfbr2 (network 4), a member of the
canonical Smad-dependent TGF-β signaling cascade, involved in
hepatic progenitor cell activation (Ding et al, 2013). As evidenced
above by Δ-DHS/associated genes and RNA effects, some notable
B6C3F1-speciﬁc effects are concordant, including Src, Cdh1, or
Tgfbr2, and may represent predominantly strain-enriched signa-
tures of functional relevance (compare network lists in Figs 2C and
Figs 3C and see gene loci DHS and RNA effects illustration in Fig 4A
and B [Cdh1] and Fig 4D and E [Src]).
Strain-selective chromatin, transcriptional, and protein
expression changes in the β-catenin pathway
By systematically overlapping Δ-RNA and genes with nearby
Δ-DHS changes, we characterized 29 of 167 (17% overlap, B6C3F1)
and 3 of 25 (12% overlap, C57BL/6J) genes of concurrent RNA and
DHS effects (Fig 3D). Because the chromatin at gene promoters is
by and large constitutively opened and from the overall distal
distribution of δ-DHSs (Figs 1 and S2B and C), a limited functional
overlap between DHS/gene expression changes is expected. We
also evaluated whether alternative DHS gene assignment ap-
proaches may yield different functional overlap output. Scanning
the whole-genome TSS (n = 34,219) for δ-DHS association in
ﬂanking windows of ±5–100 kbp identiﬁed 10–26% functional
differential RNA/DHS overlap in B6C3F1 and 4–24% overlap in
C57BL/6J (Fig S5A). In a complementary approach, scanning the
differential DHS landscape for δ-RNA association in ﬂanking
windows of ±5–100 kbp identiﬁed 4–13% functional RNA/DHS
overlap in B6C3F1 and close to null in C57BL/6J (Fig S5B). The
limited overlap in the later method is expected from the larger
number of DHSs over gene expression changes in both strains.
Thus, overall using a range of gene/DHS assignment approaches
yields equivalent overlap, in the range of 10–20%. Interestingly, a
large number of DHSs can not immediately be assigned to de-
tectable gene transcriptional changes (Fig 5A) and yet may
represent a genomic landscape of functional interest (see
below).
Notably, STRING-db and literature analysis of the overlapping
gene loci highlight evidence for functional and/or biochemical
interactions with Wnt/β-catenin signaling functions (e.g., Cdh1, Klf9,
Src, Tgfbr2, Ddah1, and Ank3), a pathway strongly reported to
mechanistically contribute to PB-mediated liver tumor promotion
(Aydinlik et al, 2001; Rignall et al, 2011; Groll et al, 2016), overall
suggesting functional relevance of this concordant Δ-strain land-
scape. To verify that DHS and RNA changes (Fig 4) represent
mapped to the nearest genes and STRING-db protein–protein interaction sub-networks enriched in each group are indicated (full list available from Table S3).
(D) Illustrative summary of DHS peaks to gene assignment approach. A single gene was associated to each Δ-DHS through associating the nearest TSS. The full list of DHS-
associated genes is available from Table S2. (E) Density distribution of distances to nearest TSS for genome-wide DHS landscape compared with PB-mediated δ−DHS for
each indicated categories.
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functionally relevant changes, we next evaluated protein expres-
sion levels of a subset of candidates relevant to Wnt/β-catenin
signaling and for which well-characterized antibodies are available.
We leveraged matching liver tissue samples and ran semi-
quantitative Western blot analyses of both Cdh1 and Src, con-
ﬁrming an increase in protein levels in PB-treated B6C3F1 mice (Fig
Figure 3. Strain-selective transcriptional effects (Δ-RNA) upon PB treatment in mice.
(A) Volcano plot showing the log2 FC and P-values of all genes (light grey) from the differential tests using the C57BL/6J samples (ﬁrst row) or the B6C3F1 samples (second row). The 102
common (red), 167 B6C3F1-enriched (orange), and 25 C57BL/6J-enriched (purple) differentially expressed genes are highlighted. Dashed lines indicate selected statistical cutoffs (|log2 FC| =
0.58 andP-value corresponding to FDR= 0.01). (B) Linear correlationof Log2 FCPB treatmentRNAeffects across strains.OnlyΔ-RNAeffects supportedbyeither strainare shownandused toﬁt
the linear regression line indicatedby thedashed line. (C)Head-to-head comparison of PB-mediatedδ-RNAeffects, highlighting shared (n = 102, red box) andunique strain effects (n = 167
for B6C3F1, orange box and n = 25 for C57BL/6J, purple box). The list of transcriptionally modulated genes is available from Table S4, STRING-db protein–protein interaction sub-networks
enriched ineachgroupare indicated (full listavailable fromTableS3). (D)TheoverlayofΔ-DHS–associatedgenes (nearest TSSassignmentapproach)andΔ-RNAexpressionchangeshighlights
a short list of loci displaying both changes in chromatin accessibility and transcriptional modulation, which are unique to each strain.
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4C and F). These data highlight that a subset of PB-mediated
hepatic responses of functional relevance can be discerned at
both RNA and chromatin accessibility levels. Chromatin accessi-
bility changes, akin to PB-mediated DNA (hydroxy)methylation
effects (Thomson et al, 2013), may thus represent potential early
biomarker signatures for non-genotoxic carcinogen exposure.
Exploring transcriptional regulators of the noncoding, strain-
selective Δ-DHS landscape
The vast majority of strain-selective changes in DHSs after PB
treatment do not account for proximal changes in gene expres-
sion but may still represent important gene regulatory elements
underlying mouse strain differences in tumor promotion sensi-
tivity (Fig 5A). The cis-acting gene regulatory element landscape is
in particular strongly enriched for transcription factor–binding
sites (TFBSs) and represents critical genome regulatory in-
formation (Consortium, 2012; Shen et al, 2012; Thurman et al, 2012;
Johanson et al, 2018). We, therefore, performed TF motif enrich-
ment analysis individually on the up- or down-regulated PB-
responsive strain-selective Δ-DHS landscape for each mouse
strain. Because TF-binding motifs frequently overlap between
different TFs, we used the root motifs from the motif clustering
provided in the JASPAR database in our analysis. To strengthen the
robustness of the detectedmotifs further, we also performed de novo
motif analysis and overlapped the results with the motifs detected in
the enrichment analysis. The resulting enriched motif clusters with
associated similar de novo motifs are shown in Fig 5B and Table S5.
In this analysis, cluster 32 (Stat family members, Bcl6, and Bcl6b)
and cluster 19 (Nfat family members and Rbpj), both based on
down-regulated B6C3F1 DHS landscape gave the strongest en-
richment (low P-values, q-values, high FC enrichments, and several
good de novo motif predictions). Two additional clusters were
identiﬁed albeit less robustly using up-regulated B6C3F1-unique
DHSs: cluster 11 (Smad family members, Tbx family members, and
Srebf1/2) and cluster 12 (Fox family members). Only one cluster was
weakly identiﬁed from C57BL/6J up-regulated DHS landscape (in-
cludes Jun/Fos, Bach, and other TF motifs), despite a similar count
of strain-speciﬁc open chromatin changes (Fig 2A).
To evaluate the biological function of the different TF motifs
clusters, we ﬁrst predicted gene targets of Δ-strain DHS landscape
for each of the enriched TF clusters and ran GO term enrichment
analysis (Fig 5C and Table S5). Overall, this analysis highlighted a
number of biological functions of potential relevance to early tu-
mor development that were predominantly observed in the B6C3F1
strain after treatment with PB (e.g., change in nuclear functions,
metabolic changes, epithelial to mesenchymal transition, cell–
matrix adhesion/organization, etc.).
Figure 4. Strain-selective chromatin and transcriptional effects at Wnt/β-catenin signaling relevant to loci.
(A) Genome browser DHS tracks show B6C3F1-enriched δ-DHS effects at the Cadherin-1 (Cdh1) locus. (B) RNA-seq, counts per million (CPM) data show B6C3F1-speciﬁc
increase in Cdh1 mRNA expression. (C) Western blot analysis and quantiﬁcation show increase in Cdh1 protein expression in liver of PB-treated B6C3F1 animals.
(D) Genome browser DHS tracks show B6C3F1-enriched Δ-DHS effects at the tyrosine-protein kinase Src locus. (E) RNA-seq, CPM data show B6C3F1-speciﬁc increase in Src
mRNA expression. (F)Western blot analysis and quantiﬁcation show increase in Src protein expression in the liver of PB-treated B6C3F1 animals. Each light grey box in
the genomic browser snapshots represent a δ-DHS peak above statistical cutoffs (Log2 FC ≥ 0.58, FDR < 0.01).
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To help ﬁlter and assess functional relevance of the identiﬁed TF
motifs, we next examined individual TFs using different knowledge-
based sources such as STRING-db, GeneCards database, and lit-
erature assessments. We systematically interrogated the prior
knowledge towards relevance of the TFs in PB response, CAR ac-
tivation, Wnt signaling, and/or hepatocarcinoma.
Stat proteins are a family of seven TFs that form part of the JAK-
STAT signaling cascade. Signiﬁcant evidence support functional
implication of Stat family members in hepatocarcinoma and cross-
interactions with some of the core genes and pathways identiﬁed
from PB-mediated changes in RNA or open chromatin effects (such
as Src and TGF-β), ultimately consistent with the early tumor
promotion relevance of this cluster of TF motifs in B6C3F1 mice (see
the Discussion section). Notably, Bcl6, in the same cluster 32, is
strongly reported to functionally interact with Stat family members,
including through the regulation of interferon-γ (Madapura et al,
2017), representing one of the enriched GO biological pathway for
this cluster (Fig 5C and Table S5). Consistent with its decreased
motif activity, the tumor suppressor Bcl6B was also previously
identiﬁed to inhibit HCC metastases in vitro and in vivo (Wang et al,
2014). Likewise, and also consistent with decreased motif activity,
NFAT family members such as NFTAc1 are reported as tumor
suppressor in HCC, through inducing tumor cell apoptosis (Xu et al,
2018). Examining the up-regulated DHS-associated TF motifs
(clusters 11 and 12) also highlights core functional and biochemical
associations in liver cell proliferation control and HCC of TGFβ/
Smad proteins and pathway (Yoshida et al, 2014) or of selected Fox
TF members. For example, Foxo1 is known to be under the reg-
ulatory control of CAR (Kazantseva et al, 2014) and a direct
interactor of β-catenin in certain conditions (Liu et al, 2011).
Overall, these analyses highlight TF families that may play a role
in determining mouse strain–speciﬁc liver tumorigenic responses
to PB (Fig 5D and E). Despite an overall equivalent number of Δ-DHS
signatures in both strains, the TF motifs are particularly enriched in
PB-treated B6C3F1. Notably, some of these TFs have previously been
associated with liver tumor promotion (including the Wnt/β-cat-
enin signaling pathway), whereas others represent potentially
novel regulatory factors for this hepatic phenotype.
Discussion
Gene regulation depends on the coordinated interplay of local and
long-range chromatin interactions within the three-dimensional
space of the nucleus. In particular, it has been noted that
Figure 5. Strain-selective TF regulatory pathways
effects upon PB treatment.
(A) Most Δ-DHSs are distal to gene TSS and not
associated with signiﬁcant changes in the nearest gene
expression (δ-RNA). (B) Summary of TF motif
enrichment in down-regulated and up-regulated
Δ-DHSs relative to the full consensus set of detected
DHSs. Four clusters of motifs are shown for B6C3F1
and one for C57BL/6J (the full list available from Table
S5). The genes shown are expression-ﬁltered members
of the motif cluster sorted by average expression.
(C) GO biological pathway analysis of predicted TF
target sites in the respective Δ-DHS group. (D) Updated
model from Lempiainen et al (2013), Pouche et al
(2017) highlighting the importance of the signaling to
chromatin and novel potential TF regulatory pathways
(baseline and treatment related) in response to CAR-
activating xenobiotic exposure. (E) Predominantly
strain-selective β-catenin and additional co-effector
regulatory pathway effects (red) are likely
contributing to the chronic and long-lasting adaptive
response associated to increased tumor promotion
sensitivity in B6C3F1 mice.
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noncoding regions of the genome contain cis-acting gene regu-
latory elements (e.g., enhancers) that determine cell type–speciﬁc
functions through interactions with TFs. Importantly, the per-
turbation of enhancers has been associated with tumor devel-
opment (Davie et al, 2015; Sur & Taipale, 2016). Enhancers are
characterized by cell type–speciﬁc open chromatin structures that
enable access for speciﬁc TFs and can be efﬁciently mapped using
nuclease-based assays coupled with deep sequencing. In this
study, we have exploited well-characterized mouse strain–
speciﬁc differences in sensitivity to PB-mediated liver tumor
promotion (Table S1) to investigate the underlying molecular
mechanisms that could account for differences in phenotypic
outcome. We have focused on liver tissue–based genome-wide
proﬁling of chromatin accessibility (DNase-seq) and gene expression
(RNA-seq) to characterize early molecular perturbations of cis-acting
gene regulatory elements after exposure to tumor-promoting doses
of PB. We identify quantitative differences in PB-induced hepatic
molecular pathways and gene regulatory networks between two
mouse strains thatmay account for differences in their sensitivity
to liver tumor promotion. These observations also provide an
entry point for investigating potential links between mouse
strain–speciﬁc genetic variation and liver-speciﬁc gene regulatory
landscapes after PB exposure.
Our molecular analysis on total liver reveals PB-induced chro-
matin accessibility and transcriptional changes that are either
common to resistant (C57BL/6J) versus sensitive (B6C3F1) mouse
strains or predominantly strain selective. Most chromatin ac-
cessibility changes take place at distal regulatory regions con-
sistent with an important role of cis-acting gene regulatory
elements in mediating early hepatic molecular responses to PB.
We interrogated the function of the distal regulatory regions by
mapping to the most proximal gene annotation (based on the
position of the gene TSS) and by investigating TF motifs associated
with changes in chromatin accessibility. These complementary
approaches were integrated with gene expression and GO-based
pathway analyses to highlight candidate groups of genes and/or
molecular pathways associated with the early stage of PB-mediated
non-genotoxic hepatocarcinogenesis. Importantly, these analyses
highlighted quantitative differences between sensitive and re-
sistant mouse strains in molecular pathways known to be asso-
ciated with PB-mediated liver tumor promotion including Wnt/
β-catenin signaling.
In addition, we also identiﬁed candidate TF regulators via PB-
mediated changes in chromatin accessibility that may represent
novel early biomarkers signatures of PB-mediated hepatocarcino-
genesis. Our observation of down-regulation of DHSs containing
Stat/Bcl6 family TF motifs (cluster 32) is suggestive of reduced Stat
signaling activity in PB-treated B6C3F1 mice. There is signiﬁcant
evidence for a role of RAS and JAK/STAT pathway activation in HCC
and therapeutic modulation of these pathways for the treatment
of human liver cancer is being actively explored (Calvisi et al,
2006). Recent studies have also elucidated speciﬁc functions for
JAK and STAT protein family members in Non Alcoholic Steato
Hepatitis (NASH) and HCC (Grohmann et al, 2018; Kaltenecker
et al, 2018). Genetic disruption of Stat5 activity in a mouse model
for liver ﬁbrosis was associated with elevated TGF-β levels and
enhanced growth hormone-induced Stat3 activity, ultimately
contributing to the development of chronic liver disease (Hosui
et al, 2009). Furthermore, STAT3 has been reported to confer
hepatoprotective or oncogenic functions depending on the extent
and duration of additional stressors, including inﬂammation
(Wang et al, 2011). Consistent with our observations of reduced
Stat pathway–associated TF activity in PB-treated mice, Stat5b
expression levels were reported to be suppressed in the livers of
mice treated with CAR activators, including PB (Oshida et al, 2016).
Interestingly, we also observed up-regulation of DHSs having TF
motifs (cluster 11) that included Smad family TFs in PB-treated
B6C3F1 mice, implying a potential increase in Smad activity. To-
gether, our data would be consistent with a previous report of
TGF-β induced SMAD signaling in hepatoma cells (Buenemann
et al, 2001), and the potential for upstream regulation of TGF-β by
Stat5 (Hosui et al, 2009).
The down-regulation of DHSs containing Bcl6 and Bcl6b TF
motifs (cluster 32) implies a reduction in Bcl6-mediated signaling in
PB-mediated B6C3F1 mice and is consistent with the low levels of
BCL6B expression that have been previously reported as a potential
prognostic biomarker for HCC (Wang et al, 2015b). Interestingly, we
previously reported Bcl6 as a candidate target of Zfp161 TF motif,
whose hepatic activity was computationally inferred to be de-
creased after PB treatment of mice and hypothesized to participate
in the regulation of quiescent hepatocyte G0–G1 transitions during
both early and late stages of PB-mediated tumorigenesis (Luisier
et al, 2014b).
The identiﬁcation of TF motifs associated with the Fox family TFs
(cluster 12) in up-regulated DHSs is suggestive of increased Fox-
mediated signaling in PB-treated B6C3F1 mice. The Forkhead box
(FOX) proteins are a family of TFs that respond to a wide range of
external stimuli and regulate diverse biological processes both
during development and throughout adult life (Golson & Kaestner,
2016). Aberrant activity of Fox family members Foxa1 and Foxa2 was
previously reported as central component of sexual dimorphism of
mouse HCC (Li et al, 2012). Likewise, the FOXQ1/NDRG1 axis was
shown to exacerbate HCC initiation via enhancing cross talk be-
tween ﬁbroblasts and tumor cells (Luo et al, 2018), and FOXO1 was
reported to contribute to HCC through a different mode of action
(Dong et al, 2017; Jia et al, 2018). Notably, FoxO1 was reported to
directly cross talk with CAR to regulate p21 expression and cell
proliferation (Kazantseva et al, 2014). Foxp1 was also reported as a
candidate hepatic target for the Zfp161 TF motif whose hepatic
activity was computationally inferred to be decreased after PB
treatment of mice (Luisier et al, 2014b).
In addition to highlighting novel TF motifs and pathways, we also
identiﬁed minimal but signiﬁcant changes in hepatic chromatin
accessibility in PB-treated B6C3F1 mice within a gene regulatory
element (an IG differentially methylated region [IG-DMR]) that
regulates the Dlk1-Dio3 imprinted gene cluster. PB was pre-
viously reported to progressively up-regulate the expression of
noncoding RNAs (including Meg3) encoded by the Dlk1-Dio3
locus in a CAR and β-catenin–dependent manner (Lempiainen et al,
2013). PB-mediated up-regulation of Meg3 localises to perivenous
hepatocytes that have been associated with Wnt-signaling dependent
stem cell–like properties (Wang et al, 2015a).Meg3 expression has also
been associated with mouse stem cell pluripotency (Liu et al, 2010;
Stadtfeld et al, 2010) and a subset of human HCCs (Luk et al, 2011),
Chromatin and gene regulatory effects in liver tumorigenesis Vitobello et al. https://doi.org/10.26508/lsa.201900461 vol 2 | no 5 | e201900461 10 of 18
suggesting that CAR activators such as PB may drive dedifferentiation
of adult hepatocytes towards a stem cell–like state during the early
stages of hepatocarcinogenesis. Interestingly, a hepatocarcinogenesis
sensitivity locus Hcs3 that was originally identiﬁed using mouse
backcrosses and linkage analysis (Dragani et al, 1991; Gariboldi et al,
1993)mapswithin a fewmegabases of theDlk1-Dio3 cluster (Drinkwater&
Ginsler, 1986; Lempiainenet al, 2013). Our data suggest amodel in which
PB-mediated transcriptional responses from this epigenetically
imprinted gene cluster may be enhanced via increased chromatin
accessibility that is mediated by B6C3F1 strain-selective genetic
factors.
The potential contributions of PB-mediated changes in he-
patic cis-acting gene regulatory elements and TFs to tumor
promotion in B6C3F1 mice will require further biochemical and
functional investigations. Nevertheless, our study highlights
several candidate TFs that may act as co-effectors during the
early stages of PB-mediated tumor promotion effects in sus-
ceptible mouse strains (Fig 5D). Most chromatin accessibility
changes take place distally from gene promoters at putative
enhancers. Enhancers are bound by regulatory TFs and serve as
integrators of intracellular and extracellular signaling pathways
to generate cell type–speciﬁc transcriptional responses
(Shlyueva et al, 2014). The functional binding of regulatory TFs at
cis-acting gene regulatory elements such as enhancers or-
chestrates long-range gene regulatory interactions within the
three-dimensional space of the nucleus, enabling cell type–
speciﬁc and spatiotemporal control of gene expression patterns
which drive cell identity and function (Thurman et al, 2012; Jin
et al, 2013; Zhang et al, 2013). Importantly, distally bound TFs can
also regulate genome functions underlying cell identity through
mechanisms that are independent of transcription (Johanson
et al, 2018). Thus, the characterization of xenobiotic-induced per-
turbations of accessible chromatin landscapes and associated TF
networks holds great potential for the identiﬁcation of patho-
physiologic mechanisms.
We recognize that the characterization of xenobiotic-mediated
tissue-speciﬁc molecular responses within tissue derived from in
vivo model systems is associated with some signiﬁcant limita-
tions. In particular, determining the speciﬁc cell types associated
with molecular responses can be challenging. Multiple biological
pathways can dynamically respond within and across cell types,
and thus, a precise linkage of molecular effects to cellular
phenotypes requires follow-up investigations (e.g., single-cell
resolution molecular proﬁling coupled with pharmacologic and/
or genetic modulation of pathway components). The functional
annotation of long-range gene regulatory interactions (e.g., en-
hancers, transcriptional factor interactions, and nuclear organi-
zation) will require follow-up locus-/pathway-speciﬁc tools and
functional analyses, including the direct biochemical mapping of
inferred TF occupancy by chromatin immunoprecipitation. Like-
wise, future work will be necessary to investigate local and global
genetic variations in context of strain-selective differences in
chromatin accessibility and TF regulation.
The epigenomic landscape is strongly responsive to environ-
mental conditions, including exposure to xenobiotics such as
chemicals and pharmaceuticals (Jirtle & Skinner, 2007; Feil & Fraga,
2012) and, thus, represents an important molecular space for
gaining potential insight into pharmacologic and toxicologic responses
to xenobiotics (Szyf, 2007; Lewis et al, 2017; Israel et al, 2018). This study
highlights the functional and toxicological relevance of hepatic epi-
genomic responses in a well-characterized rodent model for drug-
induced non-genotoxic carcinogenesis. The mapping of mouse
strain–selective pertubations of cis-acting regulatory elements (cis-
trome) provides novel TF–based insights into the molecular basis for
susceptibility to PB-induced rodent liver tumor promotion (Fig 5E).
These observations are also consistent with recently reported links
between genetic variation and tissue-speciﬁc epigenetic perturbations
after toxicant exposures (Lewis et al, 2017; Israel et al, 2018). Thus, the
integration of genetic, epigenomic, and transcriptomic data together
with phenotypic endpoints has the potential to enhance mechanism-
based safety assessment of both chemicals and pharmaceuticals. In
addition, integrated epigenomic and transcriptomic proﬁling of tissue-
speciﬁc responses to xenobiotics may also provide a valuable re-




In vivo rodent studies were performed in conformity with the Swiss
Animal Welfare Law (speciﬁcally under the animal licenses No. 2345
by Kantonales Veterinaramt Basel-Stadt [Cantonal Veterinary Of-
ﬁce, Basel]).
Animal treatment and sample preparation
As previously reported in (Lempiainen et al, 2013; Luisier et al,
2014a), male 9–11-wk-old C57BL/6J mice were obtained from
Taconic. Animals were allowed to acclimatize for at least 5 d before
being randomly divided into two treatment groups of ﬁve animals
each. 0.05% (wt/vol) PB (Ha¨nseler AG) was administered to one
group through ad libitum access to drinking water for either 1, 7, 14,
28 or 91 d. Male B6C3F1/Ctrl (C57BL/6 \ × C3H/He _) mice 4–5 wk old
were obtained from Charles River Laboratories. Animals were
allowed to acclimatize for at least 5 d before being randomly divided
into two treatment groups of ﬁve animals each. 0.05% (wt/vol) PB
(Sigma-Aldrich) was administered to one group through ad libitum
access to drinking water for 91 d. Individual mice from both studies
were checked daily for activity and behavior and sacriﬁcedon the last
day of dosing. Livers were removed before freezing in liquid nitrogen
and −80°C storage.
Nuclei preparation, DNase treatment, and DNA puriﬁcation
DNase I assay was performed as previously described by Ling and
Waxman (Ling and Waxman 2013a, 2013b) with minor modiﬁcations.
100–150 mg of frozen liver tissue was thawed on ice for 5 min and
then homogenized in 1 ml ice-cold nuclear homogenization buffer
(NEHB): 10 mM Hepes-KOH, pH 8.0, 25 mM KCl, 1 mM EDTA, 2 M
sucrose, 10% glycerol, 0.15 mM spermine, 0.5 mM spermidine, 10 mM
NaF, 1 mM orthovanadate, 1 mM PMSF, 0.5 mM DTT, and 1× protease
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inhibitor cocktail; using a 7-ml Dounce tissue homogenizer. Nuclei
were isolated by ultracentrifugation in an SW 40 Ti rotor, overlying
the homogenized tissue on top of 5 ml NEHB in a 14-ml Thinwall
Ultra-Clear 14 × 95-mm tube (cat. no. 344060; Beckman Coulter).
Centrifugation was performed at 66,000g for 1 h at 4°C. Isolated
nuclei were rinsed three times in 1 ml ice-cold buffer A: 15 mM
Tris–HCl, pH 8.0, 15 mM NaCl, 60 mM KCl, 1 mM EDTA, 0.5 mM EGTA,
0.5 mM spermidine, and 0.3 mM spermine. The pelleted nuclei
were suspended in digestion buffer (nine volumes of buffer A and
one volume of 10X DNase I digestion buffer [60 mM CaCl2, 750 mM
NaCl]) by using a Dounce homogenizer, counted using a hema-
cytometer after 100-fold dilution in PBS, and then resuspended in
ﬁnal aliquots of 250 μl containing ~3.3 × 106 nuclei each. DNase I
digestion was carried out at 37°C for 3 min using a ﬁnal concentration
of 50 U/ml of RQ1 RNase-free DNase I (cat. no. M6101; Promega). We
digested 107 nuclei per mouse. DNase digestion was stopped using 300
μl of stop buffer: 50 mM Tris–HCl, pH 8.0, 100 mM NaCl, 0.1% SDS, 100
mM EDTA, 0.5 mM spermidine, and 0.3 mM spermine. DNA puriﬁcation
was performed at 55°C overnight using 10 μl of 10 mg/ml proteinase K.
RNA digestion was carried out at 37°C for 30min using 5 μl of 10mg/ml
RNase A. DNA from different aliquots deriving from the same animal
were pooled and subsequently extracted using an equal volume
of phenol–chloroform–isoamyl alcohol and then one volume of
chloroform–isoamyl alcohol. The solution recovered from the phe-
nolic extraction was adjusted with 5 M NaCl to give a ﬁnal concen-
tration of 0.8 M NaCl and then DNA fractionation was performed in a
SW 40 Ti rotor, overlying the adjusted solution on top of 9 ml of a
sucrose step gradient (40%, 35%, 30%, 25%, 20%, 17.5%, 15%, 12.5%, and
10% solutions in 1× centrifugation buffer: 20 mM Tris–HCl, pH 8.0, 5 mM
EDTA, and 1 mM NaCl). Centrifugation was performed at 78,000g in a
14 ml Thinwall Ultra-Clear 14 × 95 mm tube for 24 h at 20°C setting
acceleration and deceleration parameters at ﬁve. After ultracentrifu-
gation, the ﬁrst 3-ml fraction was recovered and puriﬁed over a
MinElute Puriﬁcation Column (QIAGEN) and eluted in 13 μl of provided
Elution Buffer.
DNase I library preparation and sequencing
DNase I digests the entire genome with a strong preference for
regions that are devoid of nucleosomes and unoccupied by TF.
Sub-nucleosomal fragments (<145 bp) are enriched for
nucleosome-free and TF bound regions, which can be further
analyzed to obtain important insights into the functional genomic
landscape (Vierstra et al, 2014). We, therefore, size-selected the
low molecular fraction of the DNase-seq libraries and performed
76-bp paired-end (PE) sequencing, obtaining an average of 43
million fragments per sample (Table S6). Speciﬁcally, next gen-
eration sequencing libraries were prepared with the NuGEN
Ovation Ultralow System V2 with A-tailing (TECAN) from 3 to 20 ng
of input material. Inputs smaller or higher than 10 ng were am-
pliﬁed using 16 or 13 rounds of PCR, respectively. Up to nine li-
braries were pooled before size selection of the 40–250 bp fraction
on a BluePippin BDF3010 3% DF Marker Q2 cassette or PippinHT
BEF2010 2% DF Marker M1 cassette (both Sage Science) and PE 76-
bp sequencing was performed on the HiSeq 2500 using v4 re-
agents (Illumina).
Genome imputation for B6C3F1
To mitigate the impact of strain differences in read mapping and
assess chromatin variation across inbred mice (Hosseini et al, 2013),
we generated strain-speciﬁc reference sequences using known
Single Nucleotide Polymorphisms (SNPs) from the Mouse Genomes
Project (Keane et al, 2011; Doran et al, 2016). We used the mm10
reference genome (C57BL/6J strain) as reference for the C57BL/6J
samples, subselecting chromosomes chr1-19, X and Y using SAMtools
faidx v0.1.19 (Li et al, 2009) for analysis. To impute the genome of
B6C3F1, we downloaded the SNPs of the parental strain C3H/HeJ from
the Mouse Genomes Project (C3H_HeJ.mgp.v5.snps.dbSNP142.vcf).
After sorting using VCFtools v0.1.14 (Danecek et al, 2011), we in-
troduced the C3H/HeJ-speciﬁc SNPs into themm10 genomeusing the
FastaAlternateReferenceMaker from the Genome Analysis Toolkit
(McKenna et al, 2010). We generated index ﬁles with SAMtools faidx.
Finally, to conﬁrm the expected genotypes for each strain, we
compared chromosomal sizes from mm10, C57BL/6J, and C3H/HeJ
and manually inspected several loci with the Integrative Genomics
Viewer v2.3 (Robinson et al, 2011; Thorvaldsdottir et al, 2013).
DNase-seq data pre-processing
Libraries were demultiplexed using bcl2fastq version 2.17. Illumina
adaptor sequences at the end of the reads were removed using
Cutadapt v1.8 and resulting reads with a minimum length of 30 bp
were retained. All samples were aligned to the mm10 reference
genome using Bowtie2 v2.1.0 (Langmead & Salzberg, 2012) with the
following parameters: -I 50 -X 400 –fr –no-mixed –no-discordant.
Binary Alignment Map (Bam) ﬁles were created from sam ﬁles and
coordinate sorted using SAMtools. PCR and optical sequencing du-
plicates were ﬂagged using Picard Tools’MarkDuplicates v1.107(1667).
Only properly paired, unique reads with amap quality score above 12
were retained after ﬁltering using SAMtools. Bam ﬁles of the same
biological replicate frommultiple sequencing runs were merged and
again ﬁltered for PCR or optical sequencing duplicates.
In addition, we mapped the B6C3F1 samples to the imputed C3H/
HeJ genome and compared the results of the alignments with the
two different reference genomes using bamUtil diff with options
–mapQual–mate. Under these conditions, no differences were
detected in common read pairs, and less than 50–100 read pairs
resulted to be unique for one or the other alignment. Hence, we
decided to use the alignment to the mm10 reference for all
downstream analysis.
Re-mapping of the encyclopedia of DNA elements (ENCODE) liver
data
The mouse DNase-seq and ChIP-seq data were integrated from
mouse ENCODE (GSE37074 and GSE31039, respectively). FASTQ ﬁles
were retrieved from NCBI SRA (https://www.ncbi.nlm.nih.gov/sra)
and processed with the same pipeline above.
DHS calling and differential analysis on DNase-seq data
DHSs were identiﬁed and bedGraphs were created applying a
q-value cutoff (−q) of 0.01 using MACS2 v2.1.1.20160309 (Zhang et al,
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2008). Differential peak analysis was performed in R 3.2.3 using the
Bioconductor package DiffBind v1.16.3 (Ross-Innes et al, 2012).
Consensus peaks for each condition were created using dba.counts
requiring that at least three samples show a signiﬁcant peak in the
same genomic window (minOverlap = 3). The DBA_EDGER method
was used to call differential peaks including treatment and strain in
the contrast. Regions showing an absolute log2 fold-change |log2
FC| ≥ 0.58 between selected contrasts and a FDR ≤ 0.01 (Benjamini–
Hochberg) are called differential.
DHS coverage proﬁle
Coverage proﬁles were generated from the bam ﬁles by counting
reads in 50-bp bins within the 5-kb region centered at the midpoint
of each consensus DHS. The bamProﬁle function in the bamsignals
(v1.12.1) R package was used setting the PE ﬂag to “ignore.” The
proﬁles were scaled to the average across samples of the total
number of reads falling into the consensus DHSs.
Overlapping DHSs with gene annotation
To assign DHSs to promoters, intra-, or intergenic elements, the
function assignChromosomeRegion in the ChIPpeakAnno v3.16.1 R
package (Zhu et al, 2010; Zhu, 2013) was used on the UCSC known
gene annotation (https://genome.ucsc.edu/). DHSs assigned to the
categories ﬁveUTRs, threeUTRs, Exons, or Introns were called in-
tragenic, whereas DHSs assigned to the categories Intergenic. Re-
gion and Immediate Downstreamwere called Intergenic (categories
as per R package).
Browser track visualization of DNase-seq data
For visualization of individual loci, edgeR-normalized DNase-seq
tracks were produced converting BAM ﬁles into BedGraphs using
BEDtools 2.24.0 genomecov with –bg and –scale parameters (Quinlan,
2014). Sizes of the libraries were obtained from the dba.analyse object
(bFullLibrarySize = TRUE). Scaling factors were calculated by di-
viding the minimum library count by the size of each individual
library. Bigwig ﬁles were compiled from normalized BedGraphs
using bedGraphToBigWig v4. Coverage of individual loci were plotted
in R3.5.0 using the wiggleplotr 1.6.1 R package.
Assigning DHSs to closest TSS
DHSs were mapped to the closest TSS using the chipenrich v2.6.1 R
package (Welch et al, 2014) and the predeﬁned locus deﬁnition
nearest_tss for the mm10 genome.
STRING-db sub-network enrichment analysis
The STRINGdb v1.22.0 R package (Franceschini et al, 2013) was used
to identify enriched protein–protein interaction sub-networks
among predeﬁned gene sets. The complete network (version 10)
for theMus Musculus (10,090) organism was selected and only gene
symbol that mapped to STRINGdb IDs were retained. Sub-networks
were identiﬁed using the Walktrap community-ﬁnding algorithm
implemented in igraph v.1.2.4.
Total RNA extraction and sequencing
25–50 mg of frozen liver material was used for total RNA extraction
using 1 ml TRIzol reagent (cat. no. 15596026; Thermo Fisher Sci-
entiﬁc). Samples were homogenized using a MagNA Lyser ho-
mogenizer (Roche) using two runs of 30 s at 6,500 rpm. Aliquots of
~600 μl of homogenized material were transferred into pre-spun
2-ml Phase Lock Gel-Heavy tubes (5Prime) and incubated for 5 min at
room temperature. 100 μl chloroform–isoamyl alcohol was added
to each aliquot. The tubes were shaken vigorously for 15 s and
incubated for 2 min. The tubes were centrifuged at 12,000g for 10
min at 4°C allowing phase separation. Sample-matching upper
aqueous phases were pooled into new pre-spun 2-ml Phase Lock
Gel-Heavy tubes and additional 200 μl chloroform–isoamyl alcohol
was used to perform a second phase separation. Aqueous phases
were then measured and transferred into fresh tubes where RNA
precipitation with 0.5 ml isopropyl alcohol was performed. After 10-
min incubation, the samples were centrifuged at 12,000g for 10 min
at 4°C. The precipitated RNA was washed once by using 1 ml 75%
ethanol before resuspension in EB buffer (QIAGEN). The samples
were NanoDrop-quantiﬁed and the RNA integrity numbermeasured
using an Agilent RNA 6000 Nano Kit (cat. no. 5067-1511; Agilent
Technologies) on a BioAnalyzer instrument. Samples with RNA in-
tegrity number above 8 were used for sequencing. Illumina libraries
were prepared with the TruSeq Stranded Total RNA Sample Prepa-
ration kit with Ribo-Zero Gold from 100 or 150 ng of input RNAusing 13
or 12 rounds of PCR for ampliﬁcation, respectively. We generated PE
76-bp reads on a HiSeq 2500 using v4 reagents (Illumina).
RNA-seq data processing
Libraries were demultiplexed and then passed to the STAR v2.4.0f1
aligner (Dobin et al, 2013) to map reads to the UCSC reference
genome mm10. The resulting bam ﬁles were sorted using SAMtools.
Bam ﬁles of the same biological replicate from different sequencing
runs were merged and ﬁltered using SAMtools with options -q 255
and -F 512. To quantify gene expression, reads overlapping genes in
the UCSC RefSeq gene annotation were counted using the sum-
marizeOverlap function (with parameters mode = “Union,” single-
End = FALSE, ignore.strand = FALSE, and fragments = TRUE) of the
GenomicAlignments (v1.6.3) R package.
Differential gene expression analysis on RNA-seq data
EdgeR (v.3.12.1) (Robinson et al, 2010; McCarthy et al, 2012) was used
to perform differential expression analysis on the count matrix.
Only genes that show CPM ≥ 0.4 in at least three samples per
treatment-strain group in at least one group were retrained for
analysis. Normalization factors to scale for library size were cal-
culated using the trimmed mean of M values (TMM) method. The
design is based on assigning each sample to a treatment-strain
group. The glmQLFit and glmQLFTest methods were used to ﬁt a
quasi-likelihood negative binomial generalized log-linear model
and to perform gene-wise tests for differential expression. Dif-
ferentially expressed genes were identiﬁed as genes showing at
least |log2 FC| ≥ 0.58 between selected contrasts and a FDR ≤ 0.01.
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TFBS enrichment
We searched the different groups of DHSs for enrichment of TF
binding sites using the HOMER software (Heinz et al, 2010). We
performed both, de novo motif analysis and enrichment analysis of
known TF motifs and overlapped the results to strengthen the
robustness of the identiﬁed motifs.
For the enrichment analysis, we obtained known TF bindingmotifs
from the JASPAR database (Khan et al, 2018). Because motifs of
different TFs can be very similar, we used the root motifs from the TF
motif clustering provided in the JASPAR database as input for HOMER.
The score cutoffs to call binding sites were optimized for each root
motif by running HOMER’s ﬁndMotifs on all DHSs and taking the score
that deﬁned the 88% quantile based on the resulting score distri-
bution. Finally, we ran HOMER’s ﬁndMotif on the individual DHS
groups providing the fasta ﬁles of all DHS regions for background
parameter calculation and obtained enrichment and de novo
analysis results. The Regulatory Sequence Analysis Tools (RSAT)
(Nguyen et al, 2018) compare-matrices tool with default values was
used to correlate de novo analysis-derived TF motifs with the known
root motifs. We overlapped the results by assigning each known root
motif the de novo motif with highest correlation.
Protein extraction, concentration measurement, and
immunoblotting
Liver tissue was dissociated in ice-cold Radioimmunoprecipitation
assay (RIPA) buffer (89900; Pierce) complemented with proteases
and phosphatases inhibitors (P8340, P2850, and P5726-1/100 each;
Sigma-Aldrich) using the Covaris ultrasound homogenizer. Liver
lysates were centrifuged (15 min, 16,000g, 4°C) and supernatants
collected and stored at −80°C. SDS–PAGE samples were prepared in
NuPAGE 4× buffer (NP0007; Invitrogen) and 10× reducing agent
(NP0004; Invitrogen) or in 6× loading buffer (60 mM Tris, pH 6.8, 2%
SDS, 9.8% glycerol, bromophenol blue, 0.6 mM DTT). Samples were
heated (10 min, 70°C), centrifuged (3 min, 14,000g), and resolved on
Invitrogen NuPAGE Bis-Tris gels (4–12% or 8% gel, MES running
buffer, 160 V, 1 h). The gels were transferred to nitrocellulose
membranes (20 V, 7 min) using the I-Blot system (#IB1001EU;
Invitrogen). Membranes were blocked for 1 h in Odyssey Blocking
Buffer (LI-COR 927-40000)/PBS (1:1) and subsequently incubated
overnight at 4°C with primary antibodies (anti-Src, CST2123, rabbit
polyclonal IgG, 1:1,000; anti–E-Cadh, CST3195, rabbit polyclonal IgG, 1:
1,000; anti-actin, A5060; Sigma-Aldrich, rabbit polyclonal IgG, 1:
15,000) diluted in Odyssey Blocking Buffer/PBS-Tween 0.1% (1:1).
After washing three times with PBS-Tween 0.1%, the membranes
were incubated for 1 h with secondary antibodies labelled with
IRdyes diluted in Odyssey Blocking Buffer/PBS-Tween 0.1% (1:1). The
membranes were washed (three times with PBS-Tween 0.1% and
three times with PBS) and dried before scanning using the Odyssey
Infrared Imaging System (LI-COR). Integrated intensities of the
protein bands of each target were quantiﬁed in their respective
ﬂuorescent channels using Odyssey software (background sub-
traction top/bottom of quantiﬁed band). The integrated intensity for
Src and E-Cadh were normalized to the integrated intensity for actin
and displayed as % of control.
Data Deposition
All data generated in this manuscript are included in the NCBI GEO
under the accession number GSE131344.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900461.
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